In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (02/2008)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Scaffolds in Tissue Engineering," features profiles of BioCeramic Therapeutics, Histogen, Humacyte and Tissue Regenix. Plus these Start-Ups Across Health Care: Braintact, CleveX, Coherex Medical and Lytix Biopharma.

You may also be interested in...



Tissue Regenix Ltd.

Tissue Regenix is developing what it describes as "de-cellularized biological scaffolds," which are meant to function like native tissue. Tissue Regenix uses tissue taken from pigs or cows as its starting material, then carefully strips out cells, leaving behind a complex matrix of proteins such as collagen and elastin. Once this matrix is implanted, the body's own cells go into it and encourage cell recruitment and tissue formation.

BioCeramic Therapeutics Ltd.

BioCeramic Therapeutics was formed around separate regenerative medicine technologies that it believes have broad potential. First up is a strontium containing glass-based material for use as a bone filler and a coating for metal implants used in various orthopedic and orthodontic procedures. The company is also developing a nanostructured synthetic extracellular matrix that could address the regeneration of hard and soft tissues, with the potential one day to allow almost any tissue to be grown.

Histogen Inc.

Histogen is developing an extracellular matrix aimed at the aesthetics market as well as wound healing and research applications. Its technology derives from fibroblasts isolated from newborns, which are then seeded onto a bead-like structure and provided with growth media, where they secrete extracellular matrix proteins and growth factors. Because the fibroblasts come from newborns, they proliferate more rapidly and can last longer than fibroblasts from adults.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL063944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel